Capital Flows

Showing 7187 articles
Business

Twist Bioscience Raises Revenue Outlook on Surging AI-Driven Demand, Spotlighting Growth and Volatility

Synthetic biology firm Twist Bioscience has lifted its full-year revenue guidance, citing robust demand for its AI-powered DNA and protein platforms. The announcement, coupled with strategic equity grants to new hires, underscores the company's aggressive push to capitalize on the booming intersection of AI and biotech, even as its long-term stock performance reveals underlying volatility.